Patents by Inventor Benjamin BOUCHERLE

Benjamin BOUCHERLE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHOD FOR SYNTHESIZING DIVERSELY SUBSTITUTED PURINES
    Publication number: 20210163484
    Abstract: The present invention relates to a method for synthesizing diversely substituted purines starting from a pyrimidine. Formula (I). The method comprises the formation of an amidine group on the pyrimidine by implementing a Vilsmeier type reagent, the functionalization of the pyrimidine with an amine and the cyclization to form the purine nucleus. Optional steps can also be performed in order to further functionalize the molecule. The invention also relates to new purines and new intermediate product.
    Type: Application
    Filed: May 3, 2017
    Publication date: June 3, 2021
    Inventors: Jean-Luc DECOUT, Renaud ZELLI, Wael ZEINYEH, Benjamin BOUCHERLE, Romain HAUDECOEUR
  • Compounds for treating cystic fibrosis
    Patent number: 10414768
    Abstract: The present invention relates to compounds of Formula (I) or pharmaceutically acceptable enantiomers, salts, solvates or prodrugs thereof. The invention further relates to the use of the compounds of Formula (I) for the treatment of cystic fibrosis. The invention also relates to a process for manufacturing compounds of Formula (I).
    Type: Grant
    Filed: December 4, 2015
    Date of Patent: September 17, 2019
    Assignees: Centre National de la Recherche Scientifique (CNRS), Université Pierre et Marie Curie—Paris 6 (UPMC)
    Inventors: Isabelle Callebaut, Jean-Paul Mornon, Jean-Luc Decout, Frederic Becq, Pierre Lehn, Brice Hoffman, Benjamin Boucherle, Romain Haudecoeur, Antoine Fortune, Clement Boinot, Julien Alliot
  • COMPOUNDS FOR TREATING CYSTIC FIBROSIS
    Publication number: 20170362239
    Abstract: The present invention relates to compounds of Formula (I) or pharmaceutically acceptable enantiomers, salts, solvates or prodrugs thereof. The invention further relates to the use of the compounds of Formula (I) for the treatment of cystic fibrosis. The invention also relates to a process for manufacturing compounds of Formula (I).
    Type: Application
    Filed: December 4, 2015
    Publication date: December 21, 2017
    Inventors: Isabelle CALLEBAUT, Jean-Paul MORNON, Jean-Luc DECOUT, Frederic BECQ, Pierre LEHN, Brice HOFFMAN, Benjamin BOUCHERLE, Romain HAUDECOEUR, Antoine FORTUNE, Clement BOINOT, Julien ALLIOT